SGLT2 inhibitors and euglycemic diabetic ketoacidosis.

MLA

Yousaf, Zohaib, et al. “SGLT2 Inhibitors and Euglycemic Diabetic Ketoacidosis.” European Journal of Clinical Pharmacology, vol. 77, no. 9, Sept. 2021, pp. 1431–33. EBSCOhost, https://doi.org/10.1007/s00228-021-03120-1.

APA

Yousaf, Z., Ata, F., Khan, A. A., Razok, A., Akram, J., Ali, E. A. H., Abdalhadi, A., Danjuma, M. I., & Al Mohanadi, D. H. S. H. (2021). SGLT2 inhibitors and euglycemic diabetic ketoacidosis. European Journal of Clinical Pharmacology, 77(9), 1431–1433. https://doi.org/10.1007/s00228-021-03120-1

Chicago

Yousaf, Zohaib, Fateen Ata, Adeel Ahmad Khan, Almurtada Razok, Jaweria Akram, Elrazi Awadelkarim Hamid Ali, Ahmed Abdalhadi, Mohammed I Danjuma, and Dabia Hamad S H Al Mohanadi. 2021. “SGLT2 Inhibitors and Euglycemic Diabetic Ketoacidosis.” European Journal of Clinical Pharmacology 77 (9): 1431–33. doi:10.1007/s00228-021-03120-1.